M&A Deal Summary |
|
---|---|
Date | 2019-06-19 |
Target | DOSE Medical |
Sector | Medical Products |
Buyer(s) | Glaukos |
Deal Type | Add-on Acquisition |
Deal Value | 3M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1998 |
Sector | Medical Products |
Employees | 907 |
Revenue | 315M USD (2023) |
Glaukos is a medical device company focused on developing ophthalmic stents for minimally invasive treatment of patients with glaucoma. Glaukos was founded in 1998 and is based in Aliso Viejo, California.
DEAL STATS | # |
---|---|
Overall | 1 of 2 |
Sector (Medical Products) | 1 of 2 |
Type (Add-on Acquisition) | 1 of 2 |
State (California) | 1 of 1 |
Country (United States) | 1 of 2 |
Year (2019) | 1 of 2 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2019-08-07 |
Avedro
Waltham, Massachusetts, United States Avedro, Inc. is a hybrid ophthalmic pharmaceutical and medical technology company focused on treating corneal disease and disorders and improving vision to reduce dependency on eyeglasses or contact lens. Avedro’s proprietary bio-activated pharmaceuticals strengthen, stabilize, and reshape the cornea to treat corneal ectatic disorders and correct refractive conditions. Avedro, Inc. was founded in 2002 and is headquartered in Waltham, Massachusetts. |
Buy | - |